COSM — Cosmos Health Inc.

Nasdaq · Consumer Discretionary · Distributors · CIK 1474167 ·
Last close
$0.26
Market Cap
$13.74M
52W High
$0.45
52W Low
$0.25
ADV30
1,467,838
Next earnings
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 17,927,892 1,381,171 -2,184,179 -2,805,423 62,369,011 514,702 42,542,652
Dec 2025 19,703,160 2,079,344 -11,243,640 -10,145,943 65,477,518 715,674 47,052,889
Sep 2025 17,110,425 2,602,618 -1,818,715 -5,352,890 69,492,758 889,441 46,357,874
Jun 2025 14,745,702 1,163,814 -2,645,319 -2,828,068 61,835,560 655,503 35,603,927

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,447,614
Investing CF
$-2,014,855
Financing CF
$14,056,091
CapEx
$-152,818
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-0.75
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-133,167,273
Inventory
$5,778,142
Receivables
$22,560,438
ST Investments
$46,158
EBIT TTM
$-16,522,363
Pretax Income TTM
$-19,144,998
Interest Exp TTM
$2,622,635
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$69,487,176
EBITDA
$-16,500,105
Free Cash Flow
$-11,263,221
Enterprise Value
$30,593,100
Total Cash
$548,927
Total Debt
$17,420,672
Shares Out
52,331,231
Trailing EPS
$-0.63
Book Value
$0.45
ROE
-92.3%
ROA
-18.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 65,271,815 -16,540,819 -19,144,998 65,477,518 47,052,889 -8,447,614
Dec 2024 54,426,402 -15,252,850 -16,183,018 54,311,892 29,778,963 -7,717,034
Dec 2023 53,376,874 -21,831,217 -18,542,654 66,014,811 29,971,783 -15,635,999
Dec 2022 50,347,652 -7,474,036 -13,830,371 68,038,621 28,381,912 -14,870,639

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.07

Max Pain — expiry 2026-07-17

max pain strike: $0.50 · spot: $0.26 · call oi: 1,559 · put oi: 4
Expected Move to 2026-07-17: ±$0.32 (119.77%) — implied range $-0.05$0.58 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MTWO M2i Global, Inc. $13.38M $0.02
EDUC EDUCATIONAL DEVELOPMENT CORP $12.43M $1.46
RWAX TAP REAL ESTATE TECHNOLOGIES, INC. $12.13M $0.00
IVFH INNOVATIVE FOOD HOLDINGS INC $16.39M $0.30
VNOV VitaNova Life Sciences Corp $11.51M $1.38

News headlines (Yahoo Finance, 1h cache)

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Gener
2026-05-26 13:34 · Yahoo
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
2026-05-21 18:20 · Yahoo
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with
2026-05-21 13:15 · Yahoo
COSM Shows Rapid Revenue Rise
2026-05-21 11:22 · Yahoo
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents u
2026-05-14 13:00 · Yahoo
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
2026-05-12 14:15 · Yahoo
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
2026-05-11 18:25 · Yahoo
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
2026-05-08 15:25 · Yahoo
COSM Introduces New Product for Sexual Health
2026-05-06 16:11 · Yahoo
Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
2026-05-06 14:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.